NASDAQ:SRGA - Surgalign Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.33
  • Forecasted Upside: 87.59 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.31
▲ +0.03 (1.32%)
1 month | 3 months | 12 months
Get New Surgalign Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRGA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRGA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$4.33
▲ +87.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Surgalign in the last 3 months. The average price target is $4.33, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 87.59% upside from the last price of $2.31.
Buy
The current consensus among 4 investment analysts is to buy stock in Surgalign.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/3/2021BTIG ResearchInitiated CoverageBuy$4.00High
i
2/2/2021Piper SandlerInitiated CoverageOverweight$4.00Low
i
11/30/2020Lake Street CapitalInitiated CoverageBuyLow
i
10/26/2020JMP SecuritiesLower Price TargetMarket Outperform$6.00 ➝ $5.00High
i
(Data available from 3/8/2016 forward)
Surgalign logo
Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $2.31
$2.25
$2.35

50 Day Range

MA: $2.38
$1.68
$3.12

52 Week Range

Now: $2.31
$1.46
$3.97

Volume

14,975 shs

Average Volume

2,271,688 shs

Market Capitalization

$188.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Surgalign?

The following Wall Street sell-side analysts have issued research reports on Surgalign in the last twelve months: BTIG Research, JMP Securities, Lake Street Capital, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for SRGA.

What is the current price target for Surgalign?

3 Wall Street analysts have set twelve-month price targets for Surgalign in the last year. Their average twelve-month price target is $4.33, suggesting a possible upside of 87.6%. JMP Securities has the highest price target set, predicting SRGA will reach $5.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $4.00 for Surgalign in the next year.
View the latest price targets for SRGA.

What is the current consensus analyst rating for Surgalign?

Surgalign currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRGA will outperform the market and that investors should add to their positions of Surgalign.
View the latest ratings for SRGA.

What other companies compete with Surgalign?

How do I contact Surgalign's investor relations team?

Surgalign's physical mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The company's listed phone number is 877 343 6832 and its investor relations email address is [email protected] The official website for Surgalign is www.surgalign.com.